1125780-43-9

Basic information

• Product Name: N-methyl-4-(4-(4-(trifluoromethyl)benzamido)phenoxy)picolinamide
• Synonyms: N-methyl-4-(4-(4-(trifluoromethyl)benzamido)phenoxy)picolinamide
• CAS NO: 1125780-43-9
• Molecular Weight: 415.372
• Mol File: 1125780-43-9.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: N-methyl-4-(4-(4-(trifluoromethyl)benzamido)phenoxy)picolinamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-methyl-4-(4-(4-(trifluoromethyl)benzamido)phenoxy)picolinamide(1125780-43-9)
• EPA Substance Registry System: N-methyl-4-(4-(4-(trifluoromethyl)benzamido)phenoxy)picolinamide(1125780-43-9)

Safety Data

• Hazardous Substances Data: 1125780-43-9(Hazardous Substances Data)

Upstream product

• 98-98-6 2-Picolinic acid 
• 51727-15-2 4-chloro-2-pyridine carboxylic acid chloride hydrochloride 
• 220000-87-3 4-chloro-N-methylpicolinamide 
• 123-30-8 4-amino-phenol 
• 284462-37-9 4-(4-aminophenoxy)-N-methylpyridine-2-carboxamide 
• 329-15-7 4-trifluoromethyl-phenyl acetyl chloride 

Relevant articles and documents

Synthesis and biological evaluation of novel 4-(4-formamidophenylamino)-N-methylpicolinamide derivatives as potential antitumor agents

A novel series of 4-(4-formamidophenylamino)-N-methylpicolinamide derivatives were synthesized and evaluated against different tumor cell lines. Experiments in vitro showed that these derivatives could inhibit the proliferation of two kinds of human cancer cell lines (HepG2, HCT116) at low micromolar concentrations and the most potent analog 5q possessed broad-spectrum antiproliferative activity. Experiments in vivo demonstrated that 5q could effectively prolong the longevity of colon carcinoma-burdened mice and slow down the progression of cancer cells by suppression of angiogenesis and the induction of apoptosis and necrosis.

Sorafenib derivatives induce apoptosis through inhibition of STAT3 independent of Raf

STAT3 is a transcription factor that modulates survival-directed transcription. It is persistently activated in many human cancers. Literature has shown that sorafenib, Raf kinase inhibitor, reduces Phospho-STAT3 and induces cell death. A series of sorafenib derivatives were synthesized as new inhibitors for STAT3. Urea, sulfonamide, and carboxamide linkers brought out different SARs from the end of sorafenib. Urea and carboxamide linked derivatives showed greater inhibition against STAT3 activity than sulfonamide linked derivatives. In particular, 1-(4-chloro-3-(trifluoromethyl)phenyl)-3-(4- (4-cyanophenoxy)phenyl)urea (1), a urea linker, was as potent as sorafenib in reducing P-STAT3 level and cell death but no inhibition for Raf activity. Such result provides a new lead for the design of STAT3 inhibitors.